Pfizer to expand portfolio of generic medicines in Korea

Published: 2011-05-26 06:57:00
Updated: 2011-05-26 06:57:00
Pfizer Korea is considering marketing medicines that are no longer patent protected, under its Established Products Business Unit strategy.

To this end, the company received Friday the approval of gemcitabine 200 mg and 1000 mg from the Food and Drug Administration.

“We will dramatically ch...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.